With the advent of breast cancer screening programs, the majorities of patients with newly diagnosed breast cancer are diagnosed with early stage disease and are likely to experience cure with proper treatment. Significant advances have been made in the management of early-stage breast cancer to personalize treatment according to disease biology. This progress has led to improvement in survival outcomes and quality of life for our patients. In this review, we discuss landmark clinical trials in medical oncology that have shaped the current standard of care for early stage ER-positive, HER2-positive, and triple negative breast cancer.
Keywords: Adjuvant; Breast cancer; Clinical trials; HER-2; Hormone receptor; Neoadjuvant trastuzumab; Pertuzumab; T-DM1; Trastuzumab emtansine; Triple negative.
Copyright © 2020 Elsevier Inc. All rights reserved.